Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Federal Trade Commission
Cipla
Argus Health
Chinese Patent Office
Mallinckrodt
Fuji
Accenture
Moodys

Generated: May 25, 2018

DrugPatentWatch Database Preview

Oxymetazoline hydrochloride - Generic Drug Details

or, see our see our flat-rate plans

« Back to Dashboard

What are the generic sources for oxymetazoline hydrochloride and what is the scope of oxymetazoline hydrochloride freedom to operate?

Oxymetazoline hydrochloride
is the generic ingredient in four branded drugs marketed by Allergan Inc, Bayer Healthcare Llc, Johnson And Johnson, and St Renatus, and is included in four NDAs. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Oxymetazoline hydrochloride has fifteen patent family members in eleven countries.

There are three drug master file entries for oxymetazoline hydrochloride. One supplier is listed for this compound.
Summary for oxymetazoline hydrochloride
Pharmacology for oxymetazoline hydrochloride
Medical Subject Heading (MeSH) Categories for oxymetazoline hydrochloride
Synonyms for oxymetazoline hydrochloride
1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethylphenol hydrochloride
2-(3-Hydroxy-2,6-dimethyl-4-t-butylbenzyl)-2-imidazoline hydrochloride
2-(3-HYDROXY-2,6-DIMETHYL-4-TERT-BUTYLBENZYL)-2-IMIDAZOLINE HYDROCHLORIDE
2-(4-t-Butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazolinium chloride
2-(4-t-butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazoliniumchloride
2-(4-tert-butyl-3-hydroxy-2,6-dimethylbenzyl)-4,5-dihydro-1H-imidazol-1-ium chloride
2-[3-Hydroxy-2,6-dimethyl-4-t-butyl-benzyl]-2-imidazoline
2,6-Dimethyl-2-(4-tertiarybutyl-3-hydroxyphenyl)methylimidazoline hydrochloride
2,6-dimethyl-2-(4-tertiarybutyl-3-hydroxyphenyl)methylimidazolinehydrochlori
2315-02-8
3-[(4,5-Dihydro-
3-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethyl-phenol hydrochloride
315O028
4-Way Nasal Spray
6-(tert-butyl)-3-((4,5-dihydro-1H-imidazol-2-yl)methyl)-2,4-dimethylphenol hydrochloride
6-t-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethyl-phenohydrochloride
6-t-Butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol hydrochloride
6-t-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenolhydrochloride
6-tert-Butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol monohydrochloride
6-tert-butyl-3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethyl-phenol hydrochloride
6-tert-butyl-3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethylphenol hydrochloride
6-tert-butyl-3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethylphenol;hydrochloride
AB2000600
AC1L24Z6
Afrazine
Afrin
Afrin hydrochloride
afrinhydrochloride
AKOS000280887
AN-10106
Anefrin nasal
BEEDODBODQVSIM-UHFFFAOYSA-N
Benzedrex Nasal Spray 12 Hour
CCG-40216
CHEBI:7863
CHEMBL1200791
CS-2533
CTK8G2231
D01022
Dristan Long Lasting Nasal Mist
DTXSID80177729
Duration 12 Hour Nasal Spray
Duration Nasal Spray
EINECS 219-015-0
EU-0100903
FT-0082561
HE059328
HE304466
HMS1568N09
HMS1920D18
HY-B0427A
iliadinhydrochloride
K89MJ0S5VY
KB-221830
KS-5222
LLiadin Mini Paediatric
Lliadine
LP00903
LS-104147
MCULE-1133105377
MFCD00058147
MLS000038040
MLS002222207
MolPort-000-709-375
Nafrine hydrochloride
Nasivin
Nasivine
NCGC00094218-01
NCGC00094218-02
NCGC00094218-03
NCGC00094218-04
NCGC00094218-05
NCGC00261588-01
Neo-Synephrine 12 Hour
Neo-Synephrine 12 Hour NTZ
Neonabel
Nostrilla
NSC-757254
NSC757254
O 2378
Ocuclear
Ocuclear (TN)
Opera_ID_32
Operil
Oximetazoline HCl
Oxymetazoline (hydrochloride)
Oxymetazoline chloride
Oxymetazoline HCl
Oxymetazoline hydrochloride (JAN/USP)
Oxymetazoline hydrochloride [USAN:JAN]
Oxymetazoline hydrochloride [USAN:USP:JAN]
Oxymetazoline hydrochloride, >=99%, solid
Oxymetazoline hydrochloride, analytical standard
Oxymetazoline hydrochloride, European Pharmacopoeia (EP) Reference Standard
Oxymetazoline Hydrochloride, pharmaceutical secondary standard; traceable to USP and PhEur
Oxymetazoline hydrochloride, United States Pharmacopeia (USP) Reference Standard
Oxymetazoline-d4
Pharmakon1600-01500453
Phenol, 3-((4,5-dihydro-1H-imidazol-2-yl)methyl)-6-(1,1-dimethylethyl)-2,4-dimethyl-, monohydrochloride
Phenol, 3-[(4,5-dihydro-1H-imidazol- 2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethyl -, monohydrochloride
Phenol, 6-t-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethyl-, hydrochloride
Prestwick_373
Rhofade
Sch 9384
SCH-9384
SCHEMBL41247
Sinex
Sinex VapoSpray Moisturizing 12-Hour Decongestant UltraFine Mist
SMR000059324
SPECTRUM1500453
SR-01000002705
SR-01000002705-2
St. Joseph Nasal Spray for Children
Sudafed OM
Tox21_500903
UNII-K89MJ0S5VY
V0297
Vicks Sinex
W-107424

US Patents and Regulatory Information for oxymetazoline hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Healthcare Llc OCUCLEAR oxymetazoline hydrochloride SOLUTION/DROPS;OPHTHALMIC 018471-001 May 30, 1986 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Allergan Inc RHOFADE oxymetazoline hydrochloride CREAM;TOPICAL 208552-001 Jan 18, 2017 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Allergan Inc RHOFADE oxymetazoline hydrochloride CREAM;TOPICAL 208552-001 Jan 18, 2017 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Allergan Inc RHOFADE oxymetazoline hydrochloride CREAM;TOPICAL 208552-001 Jan 18, 2017 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Non-Orange Book US Patents for oxymetazoline hydrochloride

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,877,793 Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using .alpha..sub.1-adrenoceptor agonists ➤ Try a Free Trial
2,017,231,985 ➤ Try a Free Trial
8,815,929 Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using .alpha..sub.1-adrenoceptor agonists ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Cantor Fitzgerald
Julphar
Accenture
Covington
QuintilesIMS
US Department of Justice
Fuji
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.